PubRank

Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) (PIVENS)

Clinical Trial ID NCT00063622

PubWeight™ 38.44‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00063622

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010 13.33
2 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009 2.92
3 Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. Hepatology 2014 2.23
4 Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2008 2.17
5 Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011 2.15
6 Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012 1.98
7 Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014 1.73
8 Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012 1.70
9 Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009 1.26
10 Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013 1.12
11 Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013 1.10
12 Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int 2013 0.97
13 Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH). PLoS One 2012 0.96
14 Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2011 0.93
15 Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov 2015 0.93
16 Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 2012 0.91
17 Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr 2012 0.89
18 Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells. Biomed Res Int 2016 0.78
19 NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. Aliment Pharmacol Ther 2014 0.77
20 Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol 2016 0.75
Next 100